Personal information

Countries

Japan

Activities

Collapse all

Employment (1)

Department of Oncology and General Medicine, IMST Hospital, Institute of Medical Science, University of Tokyo: Minato-ku, Tokyo, JP

2021-07-01 to present | Professor (Department of Oncology and General Medicine)
Employment
Source: Self-asserted source
Narikazu Boku

Education and qualifications (1)

University of Tokyo: Tokyo, JP

Education
Source: Self-asserted source
Narikazu Boku

Works (15)

A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)

Cancer
2025-04 | Journal article
DOI: 10.1002/cncr.35807
Contributors: Nozomu Machida; Takehiro Okumura; Narikazu Boku; Junji Kishimoto; Tomohiro Nishina; Koichi Suyama; Yasuhisa Ohde; Katsunori Shinozaki; Hideo Baba; Shinya Tokunaga et al.
Source: check_circle
Crossref

Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer

Translational Oncology
2024-10 | Journal article
DOI: 10.1016/j.tranon.2024.102075
Contributors: Chie Kudo-Saito; Hiroshi Imazeki; Hiroki Ozawa; Hirofumi Kawakubo; Hidekazu Hirano; Narikazu Boku; Ken Kato; Hirokazu Shoji
Source: check_circle
Crossref

Data from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.c.6511500
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Data from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.c.6511500.v1
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Supplementary Figures S1 - S5 from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22423446
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Supplementary Figures S1 - S5 from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22423446.v1
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Supplementary Methods from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22423443
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Supplementary Methods from IL33 Is a Key Driver of Treatment Resistance of Cancer

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22423443.v1
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

ARHGAP–RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer

Oncogene
2022-10-21 | Journal article
DOI: 10.1038/s41388-022-02469-6
Contributors: Masayuki Komatsu; Hitoshi Ichikawa; Fumiko Chiwaki; Hiromi Sakamoto; Rie Komatsuzaki; Makoto Asaumi; Kazuhisa Tsunoyama; Takeo Fukagawa; Hiromichi Matsushita; Narikazu Boku et al.
Source: check_circle
Crossref

Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials

Gastric Cancer
2022-07 | Journal article
DOI: 10.1007/s10120-022-01291-z
Contributors: Eisuke Booka; Chiyo K. Imamura; Masashi Takeuchi; Hirofumi Kawakubo; Hiroya Takeuchi; Yusuke Tanigawara; Yuko Kitagawa; Narikazu Boku
Source: check_circle
Crossref

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

Gastric Cancer
2021-07 | Journal article
DOI: 10.1007/s10120-021-01173-w
Contributors: Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh et al.
Source: check_circle
Crossref

Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective

Gastric Cancer
2021-05 | Journal article
DOI: 10.1007/s10120-021-01164-x
Contributors: Masahiko Aoki; Satoru Iwasa; Narikazu Boku
Source: check_circle
Crossref

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Journal of Clinical Oncology
2021-03-20 | Journal article
DOI: 10.1200/JCO.20.00892
Contributors: Markus Moehler; Mikhail Dvorkin; Narikazu Boku; Mustafa Özgüroğlu; Min-Hee Ryu; Alina S. Muntean; Sara Lonardi; Marina Nechaeva; Arinilda C. Bragagnoli; Hasan S. Coşkun et al.
Source: check_circle
Crossref

Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)

Pancreatology
2020-09 | Journal article
DOI: 10.1016/j.pan.2020.07.010
Contributors: Ryo Shimoyama; Susumu Hijioka; Nobumasa Mizuno; Gakuto Ogawa; Tomoko Kataoka; Hiroshi Katayama; Nozomu Machida; Yoshitaka Honma; Narikazu Boku; Tetsuya Hamaguchi et al.
Source: check_circle
Crossref

IL33 Is a Key Driver of Treatment Resistance of Cancer

Cancer Research
2020-05-15 | Journal article
DOI: 10.1158/0008-5472.CAN-19-2235
Contributors: Chie Kudo-Saito; Takahiro Miyamoto; Hiroshi Imazeki; Hirokazu Shoji; Kazunori Aoki; Narikazu Boku
Source: check_circle
Crossref

Peer review (3 reviews for 3 publications/grants)

Review activity for British journal of cancer. (1)
Review activity for Nature communications (1)
Review activity for The lancet. (1)
How many people are using ORCID?